Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease - PubMed

Affiliations

• PMID: 15953415
• DOI: 10.1016/j.neuron.2005.05.010

Free article

Comparative Study

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

Eliezer Masliah et al. Neuron. 2005.

Free article

Abstract

Abnormal folding of alpha-synuclein (alpha-syn) is thought to lead to neurodegeneration and the characteristic symptoms of Lewy body disease (LBD). Since previous studies suggest that immunization might be a potential therapy for Alzheimer's disease, we hypothesized that immunization with human (h)alpha-syn might have therapeutic effects in LBD. For this purpose, halpha-syn transgenic (tg) mice were vaccinated with halpha-syn. In mice that produced high relative affinity antibodies, there was decreased accumulation of aggregated halpha-syn in neuronal cell bodies and synapses that was associated with reduced neurodegeneration. Furthermore, antibodies produced by immunized mice recognized abnormal halpha-syn associated with the neuronal membrane and promoted the degradation of halpha-syn aggregates, probably via lysosomal pathways. Similar effects were observed with an exogenously applied FITC-tagged halpha-syn antibody. These results suggest that vaccination is effective in reducing neuronal accumulation of halpha-syn aggregates and that further development of this approach might have a potential role in the treatment of LBD.

Similar articles

• Lysosomal pathology associated with alpha-synuclein accumulation in transgenic models using an eGFP fusion protein.

  Rockenstein E, Schwach G, Ingolic E, Adame A, Crews L, Mante M, Pfragner R, Schreiner E, Windisch M, Masliah E. Rockenstein E, et al. J Neurosci Res. 2005 Apr 15;80(2):247-59. doi: 10.1002/jnr.20446. J Neurosci Res. 2005. PMID: 15765523

• Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice.

  Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, Wuertzer C, Gainetdinov RR, Caron MG, Di Monte DA, Federoff HJ. Richfield EK, et al. Exp Neurol. 2002 May;175(1):35-48. doi: 10.1006/exnr.2002.7882. Exp Neurol. 2002. PMID: 12009758

• An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model.

  Hashimoto M, Rockenstein E, Mante M, Crews L, Bar-On P, Gage FH, Marr R, Masliah E. Hashimoto M, et al. Gene Ther. 2004 Dec;11(23):1713-23. doi: 10.1038/sj.gt.3302349. Gene Ther. 2004. PMID: 15483670

• Alpha-synuclein and transgenic mouse models.

  Fernagut PO, Chesselet MF. Fernagut PO, et al. Neurobiol Dis. 2004 Nov;17(2):123-30. doi: 10.1016/j.nbd.2004.07.001. Neurobiol Dis. 2004. PMID: 15474350 Review.

• Transgenic models of alpha-synuclein pathology: past, present, and future.

  Hashimoto M, Rockenstein E, Masliah E. Hashimoto M, et al. Ann N Y Acad Sci. 2003 Jun;991:171-88. Ann N Y Acad Sci. 2003. PMID: 12846986 Review.

Cited by

• Altered serum IgG levels to α-synuclein in dementia with Lewy bodies and Alzheimer's disease.

  Koehler NK, Stransky E, Shing M, Gaertner S, Meyer M, Schreitmüller B, Leyhe T, Laske C, Maetzler W, Kahle P, Celej MS, Jovin TM, Fallgatter AJ, Batra A, Buchkremer G, Schott K, Richartz-Salzburger E. Koehler NK, et al. PLoS One. 2013 May 31;8(5):e64649. doi: 10.1371/journal.pone.0064649. Print 2013. PLoS One. 2013. PMID: 23741358 Free PMC article.

• Gene therapy targeting mitochondrial pathway in Parkinson's disease.

  Choong CJ, Mochizuki H. Choong CJ, et al. J Neural Transm (Vienna). 2017 Feb;124(2):193-207. doi: 10.1007/s00702-016-1616-4. Epub 2016 Sep 16. J Neural Transm (Vienna). 2017. PMID: 27638713 Review.

• Developing therapeutic antibodies for neurodegenerative disease.

  Yu YJ, Watts RJ. Yu YJ, et al. Neurotherapeutics. 2013 Jul;10(3):459-72. doi: 10.1007/s13311-013-0187-4. Neurotherapeutics. 2013. PMID: 23549647 Free PMC article. Review.

• Active poly-GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model.

  Zhou Q, Mareljic N, Michaelsen M, Parhizkar S, Heindl S, Nuscher B, Farny D, Czuppa M, Schludi C, Graf A, Krebs S, Blum H, Feederle R, Roth S, Haass C, Arzberger T, Liesz A, Edbauer D. Zhou Q, et al. EMBO Mol Med. 2020 Feb 7;12(2):e10919. doi: 10.15252/emmm.201910919. Epub 2019 Dec 20. EMBO Mol Med. 2020. PMID: 31858749 Free PMC article.

• Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements.

  Asuni AA, Boutajangout A, Quartermain D, Sigurdsson EM. Asuni AA, et al. J Neurosci. 2007 Aug 22;27(34):9115-29. doi: 10.1523/JNEUROSCI.2361-07.2007. J Neurosci. 2007. PMID: 17715348 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Molecular Biology Databases

  • Mouse Genome Informatics (MGI)

• Miscellaneous

  • NCI CPTAC Assay Portal